Tumor Lysis Syndrome in Gastrointestinal Stromal Tumor Treated with the Oral Tyrosine Kinase Inhibitor Imatinib: A Case Report

2017 ◽  
Vol 1 (1) ◽  
Author(s):  
Yuan Jeng-Nian ◽  
Li Anna Fen-Yau ◽  
Chen Chih-Yen
Keyword(s):  
Case Report ◽  
Tyrosine Kinase ◽  
Gastrointestinal Stromal Tumor ◽  
Tyrosine Kinase Inhibitor ◽  
Kinase Inhibitor ◽  
Tumor Lysis Syndrome ◽  
Stromal Tumor ◽  
Tumor Lysis

scholarly journals A Case Report of Classical Gastrointestinal Stromal Tumor with an Undifferentiated Pleomorphic Sarcoma Component

2020 ◽  
Author(s):  
YiFan Hu ◽  
SHUNHAI JIAN ◽  
bin wen ◽  
linli he ◽  
yifan huang
Keyword(s):  
Case Report ◽  
Tyrosine Kinase ◽  
Gastrointestinal Stromal Tumor ◽  
Tyrosine Kinase Inhibitor ◽  
Kinase Inhibitor ◽  
Stromal Tumor ◽  
Undifferentiated Sarcoma ◽  
Pleomorphic Sarcoma ◽  
Genetic Test Results ◽  
Mesenchymal Neoplasm

Abstract Background:Gastrointestinal stromal tumor (GIST) is the most common primary mesenchymal neoplasm of the gastrointestinal tract.a small number of GIST patients showed morphologic and immunohistochemical phenotypes change after taking the selective tyrosine kinase inhibitor imatinib.Case presentation :A 64-year-old Asian man was referred to a hospital for dizziness and anemia. Then the patient received imatinib for 11 months after the discovery of a gastric stromal tumor, and had the tumor surgically removed. We found that the classical GIST region was juxtaposed to a undifferentiated component of pleomorphic sarcoma. The genetic test results of the patient showed that the 11 exon of C-Kit gene was homozygous deletion, and the 567 codon of the 12 exon of PDGFRα was homozygous mutation. We infer that the patient showed rare dedifferentiation change after taking the tyrosine kinase inhibitors (TKIs) imatinib（IM）.Conclusions:Together with reported cases, awareness of this rare clinical entity and its potential occurrence following Tyrosine kinase inhibitor (TKI)treatment could prevent a diagnostic pitfall. The case report reminds us of the diagnosis in GIST that the possibility of dedifferentiation in GISTs should always be considered when an undifferentiated sarcoma component is identified in the gastrointestinal tract.

Effect of the Tyrosine Kinase Inhibitor STI571 in a Patient with a Metastatic Gastrointestinal Stromal Tumor

2001 ◽  
Vol 344 (14) ◽  
pp. 1052-1056 ◽  
Author(s):  
Heikki Joensuu ◽  
Peter J. Roberts ◽  
Maarit Sarlomo-Rikala ◽  
Leif C. Andersson ◽  
Pekka Tervahartiala ◽  
...  
Keyword(s):  
Tyrosine Kinase ◽  
Gastrointestinal Stromal Tumor ◽  
Tyrosine Kinase Inhibitor ◽  
Kinase Inhibitor ◽  
Stromal Tumor

scholarly journals Gastrointestinal Stromal Tumor of the Tongue

2013 ◽  
Vol 28 (1) ◽  
pp. 28-33
Author(s):  
Andrie Jeremy Formanez ◽  
Grace Naomi B. Galvan-Bravo
Keyword(s):  
Tyrosine Kinase ◽  
Gastrointestinal Stromal Tumor ◽  
Tyrosine Kinase Inhibitor ◽  
Kinase Inhibitor ◽  
Stromal Tumor ◽  
Surgical Removal ◽  
Repeat Surgery ◽  
Complete Surgical Resection ◽  
Tender Mass ◽  
Immunohistochemical Studies

Objective: To report a case of a gastrointestinal stromal tumor presenting as a recurrent tongue mass Methods: Study Design: Case Report Setting: Tertiary Public Hospital Participant: One patient Results: A 40-year-old Filipino soldier from Camarines Sur presented with a recurrent tongue mass two years after excision of a progressively-enlarging, firm, fixed, non-tender mass at the left posterior third of the tongue diagnosed as a Schwannoma. Repeat surgery involved partial glossectomy via midline mandibular swing. Final histopathologic report after immunohistochemical studies for CD117, SMA, and S100 was extraintestinal gastrointestinal stromal tumor of the tongue. The patient was started on the c-kit tyrosine kinase inhibitor Imatinib with no recurrence 10 months post treatment. Conclusion: Gastrointestinal stromal tumor may be considered when presented with a recurrent tongue mass despite complete surgical resection. Surgical removal is curative for most lesions. Post-operative chemotherapy with the use of Imatinib is valuable. Keywords: recurrent tongue mass, gastrointestinal stromal tumor, immunohistochemistry, c-kit tyrosine kinase inhibitor

scholarly journals Antitumor Effect of the Tyrosine Kinase Inhibitor Nilotinib on Gastrointestinal Stromal Tumor (GIST) and Imatinib-Resistant GIST Cells

PLoS ONE ◽  
2014 ◽  
Vol 9 (9) ◽  
pp. e107613 ◽  
Author(s):  
Hiroyuki Sako ◽  
Kazumasa Fukuda ◽  
Yoshiro Saikawa ◽  
Rieko Nakamura ◽  
Tsunehiro Takahashi ◽  
...  
Keyword(s):  
Tyrosine Kinase ◽  
Gastrointestinal Stromal Tumor ◽  
Tyrosine Kinase Inhibitor ◽  
Antitumor Effect ◽  
Kinase Inhibitor ◽  
Stromal Tumor ◽  
Imatinib Resistant
Sign in / Sign up

Export Citation Format

Share Document